Aakaar Medical Technologies to Review September 2026 Results

Aakaar Medical Technologies Limited has informed the exchange that its board will meet on October 30, 2026, to consider unaudited financial results for the half year ended September 30, 2026, and employee ESOPs. The meeting follows a FY26 in which the company reported revenue of ₹67.7 crore and net income of ₹6.6 crore.

What will Aakaar Medical Technologies Limited's board consider on October 30?

Aakaar Medical Technologies Limited's board is scheduled to consider and approve the company's half-yearly unaudited financial results for the period ended September 30, 2026. The company disclosed the proposed board meeting to the exchange, identifying the review of financial results as the first agenda item.

The board will also consider ESOPs for employees. The available disclosure does not specify the proposed number of options, eligibility criteria, exercise price, vesting conditions, or the expected financial effect of any employee stock option plan. Those details, if approved and disclosed, would be relevant for shareholders assessing the plan's potential dilution and its role in employee compensation.

The announcement is a meeting intimation rather than a release of the September 2026 financial statements. As a result, no revenue, profit, margin, cash-flow, or balance-sheet numbers for the six months ended September 2026 have been provided in the material available. The eventual unaudited results will provide the first reported view of the company's performance for that period.

The company is listed under the AAKAAR symbol, and its ISIN is INE1GYP01013. The board's consideration of the results is subject to the usual review process applicable to listed-company financial reporting. The earlier half-yearly results for September 2025 were reviewed by the audit committee and accompanied by a limited review report with an unmodified opinion from the statutory auditors.

What do Aakaar Medical Technologies Limited's FY26 results show?

Aakaar Medical Technologies Limited reported sales of ₹66.9 crore for the financial year ended March 31, 2026, compared with ₹61.6 crore a year earlier. Reported revenue was ₹67.7 crore, up from ₹61.8 crore in the previous year, while net income increased to ₹6.6 crore from ₹6.0 crore.

The annual figures indicate that the company ended FY26 with higher revenue and profit than in FY25. However, the source material does not provide a full reconciliation between the annual results and the separately reported half-yearly figures, nor does it provide segment-level results. Investors will therefore need to rely on the September 2026 filing for updated information on operating momentum after the March 2026 year-end.

A summary of the disclosed financial figures is set out below. All absolute monetary figures have been expressed in ₹ crore.

The company also scheduled an H2 and FY26 earnings conference call for May 15, 2026, after the board approved audited results for the year ended March 31, 2026. That process indicates that the company has previously used investor communication following its financial-result announcements, although no earnings-call arrangement for the September 2026 results is stated in the available information.

How did Aakaar Medical Technologies Limited perform in H1 FY26?

Aakaar Medical Technologies Limited reported revenue from operations of ₹25.3 crore in H1 FY26, compared with ₹27.7 crore in H1 FY25, representing an 8.7% year-on-year decline. EBITDA fell from ₹1.5 crore to ₹0.07 crore, and the company recorded a profit after tax loss of ₹0.8 crore, compared with a ₹0.5 crore profit in the previous corresponding period.

The H1 FY26 EBITDA margin was reported at 0.3%, versus 5.4% in H1 FY25. The profit-after-tax margin changed to negative 3.1% from a positive 1.7%. These figures show that the decline in revenue was accompanied by a much sharper reduction in operating profitability during the period.

Management attributed the first-half performance to normal seasonality, which it described as historically softer than the second half, and to a deliberate tightening of credit terms. The company also cited elevated inventory arising from post-listing regulatory transitions, revised packaging requirements and pre-emptive imports during licence renewals.

According to the disclosed H1 FY26 commentary, EBITDA was affected by one-time spending on conferences and annual meetings, along with minor foreign-exchange movements. These are management explanations for the reported numbers rather than independently quantified adjustments. The September 2026 results will be important in showing whether these factors continued, reduced, or were replaced by other operating pressures.

Why are the September 2026 results relevant for investors?

The September 2026 results are relevant because they will update investors on the company's financial performance after FY26 revenue increased to ₹67.7 crore and net income rose to ₹6.6 crore. They will also offer a comparison with H1 FY26, when revenue from operations declined and profitability turned negative.

The prior H1 FY26 results reflected a gap between the full-year outcome and the first-half trend. While the company described H1 as seasonally softer and pointed to credit and inventory-related factors, the audited FY26 figures subsequently showed higher annual revenue and net income. The forthcoming filing can provide factual evidence on the current period's revenue trajectory, margins and any changes in working-capital conditions.

The ESOP agenda is also relevant to shareholders because employee stock options can form part of retention and compensation arrangements. Yet the present disclosure provides no terms that would allow an assessment of the size or financial impact of a potential plan. Investors should distinguish between the board's consideration of ESOPs and any final plan, which would require its own disclosed details.

No share-price movement, market reaction, or analyst forecast has been provided in the source material. It would therefore be premature to draw conclusions about the likely market response. The formal financial-results announcement, and any accompanying explanatory statement, will be the key source for assessing the company's current operating and financial position.

What background explains the company's recent financial reporting?

Aakaar Medical Technologies Limited operates in India's aesthetic and dermatology sector, according to the information supplied with its earlier H1 FY26 commentary. Its reported first-half performance included lower revenue from operations and a loss, while the company linked the period to seasonal demand patterns, tightened credit practices and inventory-related regulatory requirements.

The company reported adjusted net worth of ₹47.1 crore in H1 FY26, compared with ₹14.3 crore in H1 FY25. Return on net worth was negative 1.7% in H1 FY26, against positive 3.3% in H1 FY25. These data points provide context for the half-year loss, though they do not replace the subsequent audited full-year financial statements.

Management had stated an ambition for 25% to 30% compound annual growth for FY26 and the following three years. This was a management target, not a reported result or a guaranteed outcome. The FY26 reported revenue growth from ₹61.8 crore to ₹67.7 crore provides the latest annual revenue comparison available in the supplied material.

For the September 2026 period, the board's meeting notice confirms only the matters to be considered. It does not include a management outlook, updated growth target, or details on inventory, credit cycles, regulatory approvals, or ESOP terms. Any such information should be assessed when formally released by the company.

Conclusion

Aakaar Medical Technologies Limited will place its September 2026 half-yearly unaudited results before the board on October 30, alongside a proposal concerning employee ESOPs. The meeting follows a mixed recent record: FY26 annual revenue and net income were higher year on year, while H1 FY26 showed weaker revenue from operations, lower EBITDA and a net loss.

The next item to watch is the board's formal outcome and the financial statements for the half year ended September 30, 2026. Investors will be looking for reported revenue, profitability, margin and working-capital data, as well as any disclosed terms of the proposed employee stock option plan.